Safety and efficacy of CD37-targeting naratuximab emtansine plus rituximab in diffuse large B-cell lymphoma and other Non-Hodgkin’s B-cell lymphomas – a phase 2 study

Results presented at EHA 2021

Moshe Yair Levy¹, Zhanet Grudeva-Popova², Marek Trneny³, Wojciech Jurczak⁴, Halyna Pylypenko⁵, Deepa Jagadeesh⁶, Marc Andre⁷, Sunita Nasta⁸, Dalit Rechavi-Robinson⁹, Sara Toffanin⁹, Sandrine Micallef⁹, Antoine Attinger⁹, Elisabeth Rouits⁹, Mariola Dymkowska⁹, Heidi Nauwelaerts⁹, Feng Jung Sherida Harriette Woei-A-Jin¹⁰

¹Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA;
²Department of Clinical Oncology, Medical University of Plovdiv, Plovdiv, Bulgaria;
³Charles University, General Hospital, Prague, Czech Republic;
⁴Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland;
⁵Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine;
⁶Cleveland Clinic, Cleveland, Ohio, USA;
⁷CHU Dinant-Godinne, UCL Namur, Yvoir, Belgium;
⁸Division of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;
⁹Debiopharm International SA, Lausanne, Switzerland;
¹⁰Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.